GB Sciences, Inc. (GBLX)
OTCMKTS: GBLX · Delayed Price · USD
0.0100
+0.0028 (38.89%)
Aug 30, 2024, 4:00 PM EDT - Market closed
GB Sciences Employees
GB Sciences had 3 employees as of March 31, 2023. The number of employees decreased by 2 or -40.00% compared to the previous year.
Employees
3
Change (1Y)
-2
Growth (1Y)
-40.00%
Revenue / Employee
n/a
Profits / Employee
-$453,892
Market Cap
2.92M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
GBLX News
- 1 year ago - Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform - GlobeNewsWire
- 1 year ago - Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations - GlobeNewsWire
- 1 year ago - Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients - GlobeNewsWire
- 2 years ago - TODAY: Gb Sciences' President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit - GlobeNewsWire
- 2 years ago - Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study - GlobeNewsWire
- 2 years ago - TODAY: Gb Sciences' President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference - GlobeNewsWire
- 2 years ago - Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease - GlobeNewsWire
- 2 years ago - TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article - GlobeNewsWire